Johnson & Johnson (JNJ) Shares Bought by Kwmg LLC

Kwmg LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,609 shares of the company’s stock after acquiring an additional 1,036 shares during the quarter. Kwmg LLC’s holdings in Johnson & Johnson were worth $2,501,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock valued at $136,289,000 after purchasing an additional 38,285 shares during the last quarter. Sather Financial Group Inc boosted its stake in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock valued at $1,341,000 after purchasing an additional 399 shares during the last quarter. Concentric Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 3.2% in the 2nd quarter. Concentric Wealth Management LLC now owns 26,611 shares of the company’s stock valued at $3,229,000 after purchasing an additional 813 shares during the last quarter. Narwhal Capital Management boosted its stake in shares of Johnson & Johnson by 2.5% in the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after purchasing an additional 1,010 shares during the last quarter. Finally, Cardinal Capital Management boosted its stake in shares of Johnson & Johnson by 10.6% in the 2nd quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock valued at $12,342,000 after purchasing an additional 9,767 shares during the last quarter. 66.51% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:JNJ opened at $146.03 on Thursday. The company has a market capitalization of $391.78 billion, a P/E ratio of 18.37, a PEG ratio of 2.28 and a beta of 0.59. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the company posted $1.90 EPS. On average, analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.47%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

JNJ has been the topic of several recent research reports. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, November 27th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research note on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Citigroup increased their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Finally, Raymond James increased their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $143.90.

In other Johnson & Johnson news, EVP Michael E. Sneed sold 30,943 shares of the firm’s stock in a transaction that occurred on Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the sale, the executive vice president now directly owns 70,817 shares in the company, valued at approximately $10,088,589.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at $3,528,955.50. The disclosure for this sale can be found here. Insiders have sold a total of 351,748 shares of company stock worth $51,092,647 over the last 90 days. Corporate insiders own 0.22% of the company’s stock.

WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/12/06/johnson-johnson-jnj-shares-bought-by-kwmg-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Systematic Risk and Investors

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply